MindMed to Present at Leerink’s Global Healthcare Conference 2025

Business Wire

03-04

NEW YORK, March 04, 2025--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at Leerink’s Global Healthcare Conference:

Leerink’s Global Healthcare Conference
- Format: Fireside Chat and 1x1 Meetings
- Date: March 11, 2025 at 3:40 PM ET
- Location: Miami Beach, FL
- Webcast Link: Leerink’s Global Healthcare Conference 2025

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.

About MindMed

MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on Nasdaq under the symbol MNMD.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250304577180/en/

Contacts

For Media: media@mindmed.co
For Investors: ir@mindmed.co

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2516412620"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516412620\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2516412620?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-04 20:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2516412620","market":"us","top_or_hot":-1,"title":"MindMed to Present at Leerink’s Global Healthcare Conference 2025","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"403\" src=\"https://s.yimg.com/uu/api/res/1.2/4hHknj1qFzNZCZ0aGR3DDQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/9d26eaeddf0a5c7549d9d6c1af75c522\" title=\"\" width=\"480\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>NEW YORK, March 04, 2025</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> (NASDAQ: MNMD) (the \"Company\" or \"MindMed\"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at Leerink’s Global Healthcare Conference:</p>\n<ul>\n<li><b>Leerink’s Global Healthcare Conference</b>\n<ul>\n<li>Format: Fireside Chat and 1x1 Meetings</li>\n<li>Date: March 11, 2025 at 3:40 PM ET</li>\n<li>Location: Miami Beach, FL</li>\n<li>Webcast Link: Leerink’s Global Healthcare Conference 2025</li>\n</ul></li>\n</ul>\n<p>Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.</p>\n<p><b>About MindMed</b></p>\n<p>MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on Nasdaq under the symbol MNMD.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250304577180/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>For Media:</b> media@mindmed.co <br/><b>For Investors:</b> ir@mindmed.co<br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MindMed to Present at Leerink’s Global Healthcare Conference 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMindMed to Present at Leerink’s Global Healthcare Conference 2025\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Business Wire</strong><span class=\"h-time small\">2025-03-04 20:00</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body>\n<figure>\n<img border=\"0\" height=\"403\" src=\"https://s.yimg.com/uu/api/res/1.2/4hHknj1qFzNZCZ0aGR3DDQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/9d26eaeddf0a5c7549d9d6c1af75c522\" title=\"\" width=\"480\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>NEW YORK, March 04, 2025</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> (NASDAQ: MNMD) (the \"Company\" or \"MindMed\"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at Leerink’s Global Healthcare Conference:</p>\n<ul>\n<li><b>Leerink’s Global Healthcare Conference</b>\n<ul>\n<li>Format: Fireside Chat and 1x1 Meetings</li>\n<li>Date: March 11, 2025 at 3:40 PM ET</li>\n<li>Location: Miami Beach, FL</li>\n<li>Webcast Link: Leerink’s Global Healthcare Conference 2025</li>\n</ul></li>\n</ul>\n<p>Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.</p>\n<p><b>About MindMed</b></p>\n<p>MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on Nasdaq under the symbol MNMD.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250304577180/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>For Media:</b> media@mindmed.co <br/><b>For Investors:</b> ir@mindmed.co<br/></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/mindmed-present-leerink-global-healthcare-120000193.html\">Business Wire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4547","symbol_name":"WSB熱門概念","start_time":0,"source_url":"https://finance.yahoo.com/news/mindmed-present-leerink-global-healthcare-120000193.html","article_id":"2516412620","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516412620","pubTimestamp":1741089600,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on Nasdaq under the symbol MNMD.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4547":"WSB热门概念","MNMD":"Mind Medicine (MindMed) Inc.","BK4137":"综合支持服务","HCSG":"医疗保健服务","BK4007":"制药"},"translate_title":"MindMed将出席Leerink 2025年全球医疗保健会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCSG":1,"MNMD":0.9},"content_text":"NEW YORK, March 04, 2025--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the \"Company\" or \"MindMed\"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at Leerink’s Global Healthcare Conference:\n\nLeerink’s Global Healthcare Conference\n\nFormat: Fireside Chat and 1x1 Meetings\nDate: March 11, 2025 at 3:40 PM ET\nLocation: Miami Beach, FL\nWebcast Link: Leerink’s Global Healthcare Conference 2025\n\n\nAudio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.\nAbout MindMed\nMindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on Nasdaq under the symbol MNMD.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250304577180/en/\nContacts\nFor Media: media@mindmed.co For Investors: ir@mindmed.co","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}